All In MedTech

Device Trial Radar · NCT06668402

Study of Daily Step Count and Treatment Response in Rectal Cancer (STEP-R)

Prospective Observational Study of the Association Between Daily Step Count and Treatment Response in Patients With Locally Advanced Rectal Cancer Undergoing Total Neoadjuvant Therapy: STEP-R Trial

Last checked: Nov 20, 2026Latest source record: Sep 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

160

Actual

Start

Oct 30, 2024

Primary completion

May 15, 2026

Study completion Sep 5, 2026

Sponsor

Lead sponsor
Gazi UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Oct 31, 2024

More device trials from this sponsor

Design

Study type
Observational
FDA-regulated device
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study aims to examine the impact of daily physical activity, specifically step count, on treatment outcomes and side effects in patients with locally advanced rectal cancer receiving total neoadjuvant therapy (chemotherapy and radiotherapy before surgery). Using Huawei Watch Fit 2 smartwatches, we will track participants' daily step counts, heart rate, and sleep quality. The primary hypothesis is that higher step counts and physical activity levels correlate with higher rates of complete pathological response at surgery. A secondary hypothesis is that increased physical activity may be associated with fewer or less severe side effects during treatment. Participants will wear a smartwatch and complete the EORTC QLQ-C30 Quality of Life Questionnaire and the Pittsburgh Sleep Quality Index at the beginning and end of treatment. Data from the smartwatch, including step count, heart rate changes, and sleep duration, will be reviewed weekly during routine visits. Approximately 200 patients with rectal cancer will participate, and each will be followed from the start of therapy until surgery (around 4-6 months). Total data collection is expected to take 12-15 months. This study could improve cancer care by identifying links between physical activity and treatment outcomes, supporting future exercise guidelines for oncology patients.

Conditions

  • Exercise
  • Total Neoadjuvant Treatment
  • Rectal Tumors
  • Smart Watch
  • Quality of Life (QOL)

Interventions

  • Utilizing a smartwatch to gather data on individuals receiving treatment for rectal neoplasm.Device

    Employing a smartwatch to monitor steps, sleep quality, intense physical activity, and vital signs in persons undergoing treatment for rectal carcinoma.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The rate of pathological complete response in rectal cancer patients receiving neoadjuvant therapyTime frame: 9 months

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Ankara University

    Ankara, Turkey (Türkiye)

  • Etlik City Hospital

    Ankara, Yenimahalle, Turkey (Türkiye)

  • Gazi University

    Ankara, Yenimahalle, Turkey (Türkiye)

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.